Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ COL9A1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5103380
Description
Antibody detects endogenous levels of total Collagen IX alpha 1.
COL9A1 is one of the three alpha chains of type IX collagen, which is a minor (5-20%) collagen component of hyaline cartilage. Type IX collagen is usually found in tissues containing type II collagen, a fibrillar collagen. Studies in knockout mice have shown that synthesis of the alpha 1 chain is essential for assembly of type IX collagen molecules, a heterotrimeric molecule, and that lack of type IX collagen is associated with early onset osteoarthritis. Mutations in the COL9A1 gene are associated with osteoarthritis in humans, with multiple epiphyseal dysplasia, 6, a form of chondrodysplasia, and with Stickler syndrome, a disease characterized by ophthalmic, orofacial, articular, and auditory defects.
Specifications
COL9A1 | |
Polyclonal | |
Unconjugated | |
COL9A1 | |
alpha 1 type IX collagen; alpha-1(IX) collagen chain; cartilage-specific short collagen; COL9A1; Col9a-1; Collagen alpha-1(IX) chain; collagen IX, alpha-1 polypeptide; collagen type IX alpha 1; collagen, type IX, alpha 1; DJ149L1.1.2; EDM6; MED; procollagen, type IX, alpha 1; STL4 | |
Rabbit | |
Affinity chromatography | |
RUO | |
12839, 1297 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P20849, Q05722 | |
COL9A1 | |
A synthesized peptide derived from human COL9A1(Accession P20849), corresponding to amino acid residues G424-T474. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction